CTOs on the Move

Zymergen

www.zymergen.com

 
Founded in 2013 and based in the San Francisco Bay Area, Zymergen integrates automation, machine learning, and genomics to rapidly accelerate the pace of scientific advancement. We treat the genome as a search space, leveraging machine learning to make discoveries far beyond the bounds of human intuition. In doing so, we deliver economic value, material diversity and performance capabilities not previously possible.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.zymergen.com
  • 5980 Horton Street Suite 105
    Emeryville, CA USA 94608
  • Phone: 415.801.8073

Executives

Name Title Contact Details
Dmitriy Ryaboy
Chief Technology Officer Profile

Funding

Zymergen raised $44M on 06/16/2015
Zymergen raised $130M on 10/11/2016
Zymergen raised $400M on 12/13/2018
Zymergen raised $300M on 09/08/2020

Similar Companies

Trident Health System

Trident Health is the leading provider of laboratory and mobile imaging services to the long term care community in the US. Operating in 43 states, we currently provide these services to more than 5,000 of the 16,000+ long term care facilities in the US.

Biocentric Solutions

Biocentric Solutions, Inc. is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Hecker and Associates

Hecker and Associates is a Arlington, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Verseau Therapeutics

Verseau is creating a new class of therapeutics, macrophage checkpoint modulators, to benefit patients with cancer, immune and inflammatory diseases.

Scipher Medicine

Most patients who are prescribed blockbuster therapies today don`t respond to the treatment, costing the health care industry billions in wasted drugs while patients continue to suffer. Scipher`s platform identifies which drug will work based on the patient`s fundamental disease biology, and not based on symptoms, disease classification, or medical bias. A simple test predicts which drug he/she will respond to, ensuring that most optimal treatment is prescribed from day one. The molecular data generated by our tests is then used to fuel novel target discovery to address a clear unmet medical need in patients who do not respond to any existing therapy.